Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study)

Negredo, Eugènia; Domingo, Peré; Pérez-Álvarez, Núria; Gutierrez, Mar; Mateo, Gràcia; Puig, Jordi; Escrig, Roser; Echeverría, Patricia; Bonjoch, Anna; Clotet, Bonaventura

doi:10.1093/jac/dku300

Cited by 44 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest of these trials [5] showed that, in addition to limb fat gains, switching to ABC had no significant effect on HIV-1 RNA, fasting lipids or glucose after 24 weeks. Other randomized studies [24,28,29] Low bone mineral density (BMD) has been reported in studies of HIV-infected individuals [37,38]. In a meta-analysis, the prevalence of osteoporosis was 3 times higher in HIVinfected patients than HIV-uninfected control subjects [38].…”

Section: Toxicity Issuesmentioning

confidence: 99%

“…In a meta-analysis, the prevalence of osteoporosis was 3 times higher in HIVinfected patients than HIV-uninfected control subjects [38]. Both virological and immunological factors contribute to decreased BMD in HIV-infected patients [37][38][39].…”

Section: Toxicity Issuesmentioning

confidence: 99%

“…Exposure to cART also induces bone demineralization and higher risk of fracture [37]; data suggest a lower BMD among patients receiving PI [37,40,41]. However, TDF is currently the antiretroviral drug most associated with BMD loss.…”

Section: Toxicity Issuesmentioning

confidence: 99%

“…However, TDF is currently the antiretroviral drug most associated with BMD loss. [37,42,43]. Results from several randomized clinical trials among antiretroviral naive patients have shown that initiation of cART is associated with a decrease in bone mineral density (BMD) of 2%-6% at both the hip and the spine, which occurs within the first year of treatment, with stabilization thereafter [40,[43][44][45][46][47][48][49].…”

Section: Toxicity Issuesmentioning

confidence: 99%

“…Three trials directly compared TDF/FTC with ABC/3TC and found greater decreases in BMD with TDF/FTC-based treatment [40,43,48]. Also, in a randomized clinical trial with patients with osteoporosis or osteopaenia, switching from TDF to ABC was followed by an increase of BMD in femur but not in spine [1,37]. Therefore, guidelines recommendations [1, 11,12] suggest that switching from TDF to ABC is an option in patients with osteoporosis or osteopaenia associated with TDF use.…”

Section: Toxicity Issuesmentioning

confidence: 99%

See 4 more Smart Citations

Switching antiretroviral regimes for the treatment of HIV: safety implications

Utrillo

Vidal

Puig

et al. 2016

Expert Opinion on Drug Safety

Self Cite

View full text Add to dashboard Cite

Switching cART has been a popular strategy to address safety issues throughout the antiretroviral era. The myriad of switching studies have paralleled the study and release into clinical practice of new antiretroviral drugs with different and often improved safety profiles. Most of them have been successful in improving antiretroviral toxicity while keeping HIV replication under control. However, it should be taken into account that, whenever a new drug is given, there is a possibility of new drug-related toxicity. Notwithstanding that, an increase in cART switching is foreseen, given the fact that we have a wide antiretroviral drug armamentarium and that people living with HIV are ageing and thus more prone to developing age-related co-morbidities whose therapies may entail new interactions and eventually new toxicities.

show abstract

Section: Toxicity Issuesmentioning

confidence: 99%

Section: Toxicity Issuesmentioning

confidence: 99%

Section: Toxicity Issuesmentioning

confidence: 99%

Section: Toxicity Issuesmentioning

confidence: 99%

Section: Toxicity Issuesmentioning

confidence: 99%

See 3 more Smart Citations

Switching antiretroviral regimes for the treatment of HIV: safety implications

Utrillo

Vidal

Puig

et al. 2016

Expert Opinion on Drug Safety

Self Cite

View full text Add to dashboard Cite

show abstract

Human Immunodeficiency Virus and Bone

Yin

Brown

2018

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

View full text Add to dashboard Cite

Bone metabolism is a key factor for clinical outcome of tibial plateau fractures

Krause

Alm

Berninger

et al. 2020

Eur J Trauma Emerg Surg

View full text Add to dashboard Cite

Purpose Given that tibial plateau fractures (TPF) are rare, they may pose a challenge to the treating surgeon due to their variety of complex fracture patterns. Numerous studies have identified potential fracture-specific, surgery-related, and patient-related risk factors for impaired patient outcomes. However, reports on the influence of bone metabolism on functional outcomes are missing. Methods In a retrospective multicenter cohort study, 122 TPF of 121 patients were analyzed with respect to radiological and clinical outcomes (Rasmussen) with a mean follow-up of 35.7 ± 24.9 months. The risk factor assessment included bone metabolism-affecting comorbidities and medication. Results The findings showed that 95.9% of the patients reported a good-to-excellent clinical outcome, and 97.4% reported a good-to-excellent radiological outcome. Logistic regression revealed that potentially impaired bone metabolism (IBM) was an independent risk factor for the clinical (p = 0.016) but not the radiological outcome (Table 4). Patients with 41-type B fractures and a potential IBM had a seven times higher risk to present a fair-to-poor clinical outcome [OR 7.45, 95 CI (4.30, 12.92)]. The most common objective impairment was a limited range of motion in 16.4% of the patients, especially in 41-type C fractures (p = 0.06). The individual failure analysis additionally identified surgery-related options for improvement. Conclusion This study demonstrated that potential IBM was an independent risk factor for a poor-to-fair clinical outcome.

show abstract

Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study)

Abstract: Switching from tenofovir to abacavir led to a slight improvement in femoral BMD although no differences were detected between groups. Larger studies are necessary before firm recommendations can be made on the discontinuation of tenofovir in patients with a low BMD.

Cited by 44 publications

References 16 publications

Switching antiretroviral regimes for the treatment of HIV: safety implications

Switching antiretroviral regimes for the treatment of HIV: safety implications

Human Immunodeficiency Virus and Bone

Bone metabolism is a key factor for clinical outcome of tibial plateau fractures

Contact Info

Product

Resources

About